Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P535 Effects of the Janus Kinase 1 (JAK1)-selective inhibitor filgotinib on circulating cytokines and whole-blood genes/pathways of patients with moderately to severely active Crohn’s disease (CD)

Autor: R Galien, Jacky Woo, L Zhuo, Adrian Serone, Xavier Roblin, O K Yoon, J Liu, G R D’Haens, E Grant

Publikováno v: Journal of Crohn's and Colitis. 14:S457-S458

Background A Phase 2 study of the JAK1-selective inhibitor filgotinib (FIL) dosed at 200 mg once daily for 10 weeks in moderately to severely active CD (FITZROY, ClinicalTrial.gov #NCT02048618) demonstrated significantly higher clinical remission rat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c407de38deb4a1c0ef1dc475ded8f094
https://doi.org/10.1093/ecco-jcc/jjz203.663

Zobrazit plný text záznamu

PTU-003 Filgotinib decreases inflammatory markers associated with endoscopic improvement in moderate to severely active crohn’s disease

Autor: Severine Vermeire, Xavier Roblin, Chantal Tasset, A Van der Aa, R Galien, A. M. Mirza, Jacky Woo, W Li, Adrian Serone, L Goyal, G. D'Haens, Satish Keshav

Publikováno v: IBD.

Introduction Filgotinib (FIL) is a JAK1-selective inhibitor currently in Phase III development for the treatment of ulcerative colitis and Crohn’s disease (CD). In a Phase II study in patients with moderately to severely active CD (FITZROY, Clinica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e478e1bf9f251b2168ba4cb9a1276a09
https://doi.org/10.1136/gutjnl-2018-bsgabstracts.125

Zobrazit plný text záznamu

Filgotinib, ein selektiver JAK1-Inhibitor, induziert klinische Remission und Senkung der pSTAT3-Werte in Patienten mit aktivem Morbus Crohn: Ergebnisse der Phase 2 FITZROY Studie

Autor: B Bokemeyer, Stefan Schreiber, P. Harrison, Jürgen Stein, R Galien, C Jamoul, Chantal Tasset, Ulf Helwig, A Van der Aa, Severine Vermeire, Andreas Sturm, T Kühbacher, L. Meuleners, Andreas Stallmach

Publikováno v: 72. Jahrestagung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten mit Sektion Endoskopie – 11. Herbsttagung der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie gemeinsam mit den Arbeitsgemeinschaften der DGAV.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6aa36579313539a4245a4c9231e7182c
https://doi.org/10.1055/s-0037-1604799

Zobrazit plný text záznamu

FRI0428 The JAK1-selective inhibitor, filgotinib, inhibits inflammation pathways observed in an IL23-induced psoriatic arthritis mouse model

Autor: C Saccomani, C Robin-Jagerschmidt, R Galien, Philippe Clément-Lacroix, C David, S. Dupont, Roland Blanque, A Cauvin, Maté Ongenaert

Publikováno v: Poster Presentations.

Background Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease characterized by musculoskeletal involvement and extra-skeletal manifestations such as psoriasis, uveitis and Inflammatory Bowel Disease (IBD). The importance of sev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7af00adf271654a3db41af3002fbb63e
https://doi.org/10.1136/annrheumdis-2017-eular.4911

Zobrazit plný text záznamu

THU0205 Effects of the jak1-selective inhibitor filgotinib on multibiomarker disease activity scores in patients with active rheumatoid arthritis and an inadequate response to methotrexate

Autor: Mark C. Genovese, W Li, Y Pan, Chantal Tasset, C Jamoul, L Goyal, A Van der Aa, R Galien, J Tarrant, P. Harrison

Publikováno v: Poster Presentations.

Background Filgotinib (GLPG0634, GS-6034) is an oral selective JAK1 inhibitor that has been evaluated in a 24-week phase 2B study (DARWIN 1) on the background of methotrexate (MTX) treatment in active rheumatoid arthritis (RA) patients who were MTX i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7d7652aa64cb298be4c7bc0a5bff7e41
https://doi.org/10.1136/annrheumdis-2017-eular.5738

Zobrazit plný text záznamu

THU0182 Monotherapy with the jak1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients

Autor: C Jamoul, A Van der Aa, Y Pan, J Tarrant, R Galien, P. Harrison, Chantal Tasset, W Li, A. Kavanaugh, L Goyal

Publikováno v: Poster Presentations.

Background Janus kinases (JAKs) are key proteins in the signal transduction of many cytokines and growth factors. The selective JAK1 inhibitor filgotinib (GLPG0634, GS-6034) has been evaluated in a 24-week phase 2B study (DARWIN 2) as monotherapy in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ac825746b7f24177b9b4b844462f9ad6
https://doi.org/10.1136/annrheumdis-2017-eular.5814

Zobrazit plný text záznamu

THU0206 The jak1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients

Autor: R Galien, W Li, Peter C. Taylor, Y Pan, Chantal Tasset, C Jamoul, A Van der Aa, L Goyal, Rene Westhovens, J Tarrant, P. Harrison

Publikováno v: Poster Presentations.

Background JAK1, 2, 3 and TYK2 are cytoplasmic tyrosine kinases that mediate intracellular signaling of many cytokines and growth factors. Filgotinib (GLPG0634, GS-6034) is a JAK inhibitor with high selectivity for JAK1 over other JAK family members.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8870cfa2a052ec0a0ede5501b0b563a5
https://doi.org/10.1136/annrheumdis-2017-eular.5799

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání